Sera Prognostics, Inc. (SERA) Stock Analysis

Company Overview

Sera Prognostics, Inc. (SERA) is capitalised at $79.69M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 71.

SERA last closed at $2.02 on September 4, 2026. That is +$0.04 (+2.02%) against the previous close. The 52-week range on file runs from $1.56 to $3.95. The latest close sits 29.49% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $81.00K. That is +5.19% against the prior fiscal year, when revenue was $77.00K. The same year closed with a net loss of $31.93M. Profit margin runs at 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.67.

Across the 4 fiscal years on file, revenue moves from $268.00K in 2022 to $81.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1,138.4. On price-to-sales that is 382.5 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.98. Annualized volatility over the trailing 5 years is 126.13%. The trailing one-year price return is −40.76%. Across 5 years the annualized return works out at −26.50%.

Growth & Income

The record shows no dividend for SERA.

The strongest complete calendar year on file is 2023 at +374.60%; the weakest is 2022 at −81.66%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the price is −31.53%.